Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.
More...
Linear Mode
